A roundup of all the latest news on www.globaluniversityventuring.com for our subscribers.
Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Respirion inhales $14.2m
Cystic fibrosis drug developer Respirion Pharmaceuticals has spun out from Telethon Kids Institute with capital from an Australian government-backed initiative.
NervGen Pharma holds nerve for $7.5m IPO
CWRU-licensed NervGen Pharma floated at the top of its range on the TSX Venture Exchange, with the proceeds earmarked to push its lead candidate for spinal cord injury into the clinic.
CDL reaches Oxford
Toronto’s Creative Destruction Lab accelerator network will open its first UK-based location through a partnership with University of Oxford after expanding into the US with NYU in 2018.
Scottish universities sign up…
